Drug Resistance Profiles Among HIV-1–Infected Children Experiencing Delayed Switch and 12-Month Efficacy After Using Second-Line Antiretroviral Therapy: An Observational Cohort Study in Rural China
- 1 September 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 58 (1), 47-53
- https://doi.org/10.1097/qai.0b013e318229f2a2
Abstract
Objective: To analyze the genotypic resistance profiles of HIV-infected children from rural China who were experiencing virologic failure to first-line antiretroviral therapy regimens and to evaluate 1-year regimen efficacy after switching to second-line therapy. Methods: A prospective cohort study was performed. Seventy-six children from the first rural pilot program with HIV viral load >1000 copies per milliliter on 2 consecutive occasions were studied. We analyzed genotype results and observed second-line therapy efficacy to 12 months. Results: After 33.1 (23.3, 41.1) months on first-line treatment after enrollment into national program, 98.7% of genotyped patients developed high-level resistance to nevirapine and 81.6% of patients had high-level resistance to efavirenz. High-level resistance to lamivudine was observed in 82.9%, followed by 57.9% for stavudine and 52.6% for zidovudine. In the nonnucleoside reverse transcriptase inhibitor class, the most common mutations were K103N/S at 50% and Y181C/I at 48.7%. M184V/I was the most common nucleoside reverse transcriptase inhibitor resistance mutation at 77.6%, the mutation rate for ≥3 thymidine analogue mutations, Q151M, and K65R were 33%, 12%, and 9%, respectively. After 12 months of boosted protease inhibitor-based second-line therapy, CD4 counts had on average increased 256 cells per cubic millimeter compared with switch baseline and 83.1% of patients had undetectable viral loads (<50 copies/mL). Conclusions: HIV-1-infected children who continued their first-line regimen regardless of virologic failure harbored multiple resistance mutations. Although the extent of resistance to nucleoside reverse transcriptase inhibitor class drugs would be expected to limit subsequent treatment options, the current second-line regimen remained effective during a 1-year observational period.Keywords
This publication has 24 references indexed in Scilit:
- Virologic Failure and Second-Line Antiretroviral Therapy in Children in South Africa—The IeDEA Southern Africa CollaborationJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed childrenAIDS, 2011
- Early Virologic Failure and the Development of Antiretroviral Drug Resistance Mutations in HIV-Infected Ugandan ChildrenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Declines in Mortality Rates and Changes in Causes of Death in HIV-1-Infected Children During the HAART EraJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected childrenJournal of Antimicrobial Chemotherapy, 2009
- Article Commentary: Treating an HIV-Infected Paediatric Patient: An Easy Task?Antiviral Therapy, 2009
- Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation ModelAntimicrobial Agents and Chemotherapy, 2008
- Early Antiretroviral Therapy and Mortality among HIV-Infected InfantsThe New England Journal of Medicine, 2008
- Analyses of HIV-1 Drug-Resistance Profiles Among Infected Adolescents Experiencing Delayed Antiretroviral Treatment Switch After Initial Nonsuppressive Highly Active Antiretroviral TherapyAIDS Patient Care and STDs, 2008
- Lopinavir/rotinavir: Appraisal of its use in HIV therapyDrugs of Today, 2007